Search results
Results From The WOW.Com Content Network
Lifileucel, sold under the brand name Amtagvi, is an adoptive T cell therapy used for the treatment of melanoma. [1] [2] [3]Specifically, lifileucel is a tumor-derived T cell immunotherapy composed of a recipient's own T cells.
There are two main classes of glycosylases: monofunctional and bifunctional. Monofunctional glycosylases have only glycosylase activity, whereas bifunctional glycosylases also possess AP lyase activity that permits them to cut the phosphodiester bond of DNA, creating a single-strand break without the need for an AP endonuclease.
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers.The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry.
RNA is composed of pyrimidine and purine nucleotides, both of which are necessary for reliable information transfer, and thus natural selection and Darwinian evolution. Becker et al. showed how pyrimidine nucleosides can be synthesized from small molecules and ribose, driven solely by wet-dry cycles. [11]
Changes in O-glycosylation are extremely common in cancer. O-glycan structures, and especially the terminal Lewis epitopes, are important in allowing tumor cells to invade new tissues during metastasis. [6] Understanding these changes in O-glycosylation of cancer cells can lead to new diagnostic approaches and therapeutic opportunities. [1]
pyrimidine analogues – mimic the structure of metabolic pyrimidines, the smaller bases incorporated into DNA as cytosine and thymine. Examples: 5-Fluorouracil, Gemcitabine, and Cytarabine; nucleoside analogues – nucleoside alternatives that consist of a nucleic acid analogue and a sugar. This means these are the same bases as above, but ...
Given, MUC-1 is 10 times higher in cancer cells than normal cells, [16] an over expression of MUC-1 in cancer can be indicative of aggressive, metastatic cancer, having a low response to therapy and survival rate. [5] MUC-1 also exhibits altered glycosylation and aberrant surface distribution patterns in tumor cells. [6]
The Journal of Cancer is a peer-reviewed open access medical journal covering all areas of cancer research and oncology, published by Ivyspring International Publisher. The editors-in-chief are Yan-Gao Man (Bon Secours Cancer Institute) and Naoto T. Ueno (University of Texas M. D. Anderson Cancer Center).